Law firm Levi & Korsinsky has initiated a securities class action lawsuit against REGENXBIO Inc., targeting investors who purchased company securities between February 2022 and January 2026. The complaint alleges that REGENXBIO made materially false and misleading statements regarding its RGX-111 gene therapy candidate while failing to disclose known safety concerns to the market.
The legal action follows REGENXBIO's January 28, 2026 announcement of an FDA clinical hold on the RGX-111 program after a central nervous system tumor was identified in a trial participant. The disclosure triggered a sharp market response, with REGENXBIO shares declining 17.8% on the announcement day, reflecting the severity of the regulatory setback and investor concerns regarding prior risk disclosures.
Investors who believe they suffered losses from purchasing REGENXBIO securities during the specified period are encouraged to act promptly. The deadline to file as a lead plaintiff in the class action is April 14, 2026. Interested parties should contact the law firm directly for additional information regarding their potential claims and eligibility to participate in the litigation.